Antineoplastic and Immunomodulating Agents (L)

View previous versions

Antineoplastic and Immunomodulating Agents (L)

Axel Kleemann, 

• https://doi.org/10.1002/14356007.a05_001.pub3

Antineoplastic Agents, 1. Nonhormonal

Axel Kleemann, 

• https://doi.org/10.1002/14356007.a05_001.pub2

Cancer Chemotherapy

Bernhard Kutscher, Gregory A. Curt, Carmen J. Allegra, Robert L. Fine, Hamza Mujagic, Grace Chao Yeh, Bruce A. Chabner, 

• https://doi.org/10.1002/14356007.a05_001

Axel Kleemann, 

Axel Kleemann

Hanau, Germany

Search for more papers by this author

Axel Kleemann, 

Axel Kleemann

Hanau, Germany

Search for more papers by this author

First published: 24 January 2022

https://doi.org/10.1002/14356007.a05_001.pub4

Abstract

The article contains sections titled:

1	Introduction
2	L01 Antineoplastic Agents
2.1	L01A Alkylating Agents
2.1.1	L01AA Nitrogen Mustard Analogues
2.1.2	L01AB Alkylsulfonates
2.1.3	L01AC Ethyleneimines (Aziridines)
2.1.4	L01AD Nitrosoureas
2.1.5	L01AX Other Alkylating Agents
2.2	L01B Antimetabolites
2.2.1	L01BA Folic Acid Analogues
2.2.2	L01BB Purine Analogues
2.2.3	L01BC Pyrimidine Analogues
2.3	L01C Plant Alkaloids and Other Natural Products
2.3.1	L01CA Vinca Alkaloids and Analogues
2.3.2	L01CB Podophyllotoxin Derivatives
2.3.3	L01CD Taxanes
2.3.4	L01CE Topoisomerase 1 (TOP 1) Inhibitors
2.3.5	L01CX Other Plant Alkaloids and Natural Products
2.4	L01D Cytotoxic Antibiotics and Related Substances
2.4.1	L01DA Actinomycins
2.4.2	L01DB Anthracyclines and Related Substances
2.4.3	L01DC Other Cytotoxic Antibiotics
2.5	L01E Protein Kinase Inhibitors
2.5.1	L01EA BcrAbl Tyrosine Kinase Inhibitors
2.5.2	L01EB Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
2.5.3	L01EC B-Raf Serine–Threonine Kinase (BRAF) Inhibitors
2.5.4	L01ED Anaplastic Lymphoma Kinase (ALK) Inhibitors
2.5.5	L01EE Mitogen-Activated Protein Kinase (MEK) Inhibitors
2.5.6	L01EF Cyclin-Dependent Kinase (CDK) Inhibitors
2.5.7	L01EG Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors
2.5.8	L01EH Human Epidermal Growth Factor Receptor 2 (HER2) Tyrosine Kinase Inhibitors
2.5.9	L01EJ Janus-Associated Kinase (JAK) Inhibitors
2.5.10	L01EK Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
2.5.11	L01EL Bruton's Tyrosine Kinase (BTK) Inhibitors
2.5.12	L01EM Phosphatidylinositol-3-kinase (Pi3K) Inhibitors
2.5.13	L01EX Other Protein Kinase Inhibitors
2.6	L01X Other Antineoplastic Agents
2.6.1	L01XA Platinum Compounds
2.6.2	L01XB Methylhydrazines
2.6.3	L01XC Monoclonal Antibodies (MAbs or mAbs)
2.6.4	L01XD Sensitizers Used in Photodynamic/Radiation Therapy
2.6.5	L01XF Retinoids for Cancer Treatment
2.6.6	L01XG Proteasome Inhibitors
2.6.7	L01XH Histone Deacetylase (HDAC) Inhibitors
2.6.8	L01XJ Hedgehog Pathway Inhibitors
2.6.9	L01XK Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
2.6.10	L01XX Other Antineoplastic Agents
3	L02 Endocrine Therapy
3.1	L02A Hormones and Related Agents
3.1.1	L02AA Estrogens
3.1.2	L02AB Progestogens (Gestagens)
3.1.3	L02AE Gonadotropin-Releasing Hormone Analogues
3.2	L02B Hormone Antagonists and Related Agents
3.2.1	L02BA Antiestrogens
3.2.2	L02BB Antiandrogens
3.2.3	L02BG Aromatase Inhibitors
3.2.4	L02BX Other Hormone Antagonists and Related Agents
4	Immune System and Its Modulation/Introduction
5	L03 Immunostimulants
5.1	L03A Immunostimulants
6	L04 Immunosuppressants
6.1	L04A Immunosuppressants
6.1.1	L04AA Selective Immunosuppressants
6.1.2	L04AB Monoclonal Antibodies/Tumor Necrosis Factor Alpha (TNF-α) Inhibitors
6.1.3	L04AC Monoclonal Antibodies/Interleukin Inhibitors
6.1.4	L04AD Calcineurin inhibitors
6.1.5	L04AX Other Immunosuppressants
	Abbreviations
	References

References

• 1 Kleemann-Engel-Kutscher-Reichert (2009) Pharmaceutical Substances, 5th edn, Thieme Verlag, Stuttgart and/or its online version.
  Google Scholar
• 2 Goodman & Gilman's (2011) The Pharmacological Basis of Therapeutics, 12th edn, McGraw Hill Medical, New York, et al; Section VIII, Chemotherapy of Neoplastic Diseases, Chapters 60–63, pp. 1665–1769 Herein Further Referred to as Goodman & Gilman's.
  Google Scholar
• 3Ward, R.A., et al. (2021) Challenges and Opportunities in Cancer Drug Resistance, Chem. Rev. 121, 3297–3351.
  10.1021/acs.chemrev.0c00383

  CAS PubMed Web of Science® Google Scholar
• 4 D.E.V. Wilman ed. (1990) The Chemistry of Antitumour Agents, Blackie & Son Ltd., Glasgow and London.
  10.1007/978-94-009-0397-5

  Google Scholar
• 5(a) National Cancer Institute, (2021) www.cancer.gov (last accessed May 2021);
  Google Scholar
  (b) Globocan, (2020) New Global Cancer Data. www.uicc.org/news/globocan-2020-new-global-cancer-data;
  Google Scholar
  (c) IQVIA Institute, (2019) Global Oncology Trends 2019 (May 2019).
  Google Scholar
• 6Thayer, A.M. (2008) C&EN (Chemical Engineering News) 86 (24), 17–27.
  Web of Science® Google Scholar
• 7 Goodman & Gilman's (2011) Chapter 61/I, 1677–1690.
  Google Scholar
• 8Sneader, W. (2005) Drug Discovery – A History, J. Wiley & Sons, Chichester, pp. 440–443 (History).
  10.1002/0470015535

  Google Scholar
• 9Chabner, B.A. (2011) General Principles of Cancer Chemotherapy, Goodman & Gilman's, pp. 1667–1675.
  Google Scholar
• 10Chabner, B.A., et al. (2011) Cytotoxic Agents, Goodman & Gilman's, pp. 1677–1730.
  Google Scholar
• 11Arnold, H. and Bourseaux, F. (1958) Angew. Chem. 70, 539.
  10.1002/ange.19580701705

  CAS Web of Science® Google Scholar
• 12Arnold, H., et al. (1958) Nature 181, 931.
  10.1038/181931a0

  CAS PubMed Web of Science® Google Scholar
• 13Brock, N. (1962) Arzneim.-Forsch. 8, 1.
  Google Scholar
• 14 Asta-Werke, (1962) US 3 018 302, DE-prior. 1956.
  Google Scholar
• 15Everett, J.L., et al. (1953) J. Chem. Soc. 2390.
  Google Scholar
• 16 NRDC, (1960) US 2 944 079, GB-prior. 1953.
  Google Scholar
• 17 NRDC, (1962) US 3 032 584, GB-prior.
  Google Scholar
• 18 NRDC, (1962) US 3 032 585, GB-prior. 1954.
  Google Scholar
• 19Hanby, W.E. and Rydon, H.N. (1947) J. Chem. Soc. 513.
  10.1039/jr9470000513

  CAS PubMed Web of Science® Google Scholar
• 20 Asta-Werke AG, (1966) DE 1 645 921, DE-prior. 1966.
  Google Scholar
• 21 Asta-Werke AG, (1973) US 3 732 340, DE-prior. 1967.
  Google Scholar
• 22Ozegowski, W. and Krebs, D. (1963) J. Prakt. Chem. 20, 178.
  10.1002/prac.19630200310

  CAS Web of Science® Google Scholar
• 23 Burroughs Wellcome, (1959) US 2 917 432, GB-prior. 1950.
  Google Scholar
• 24Sandberg, J.S., et al. (1972) Cancer Chemother. Rep. Part 2 30, 137.
  Google Scholar
• 25 American Cyanamid, (1954) US 2 670 347, US-prior. 1952.
  Google Scholar
• 26 American Cyanamid, (1990) US 4 918 199, US-prior. 1988.
  Google Scholar
• 27Johnston, T.P., et al. (1963) J. Med. Chem. 6, 669. (1966) J. Med. Chem. 9, 892.
  10.1021/jm00342a010

  CAS PubMed Web of Science® Google Scholar
• 28Johnston, T.P., et al. (1966) J. Med. Chem. 9, 892. (1975) J. Med. Chem. 18, 104.
  10.1021/jm00324a026

  CAS PubMed Web of Science® Google Scholar
• 29Herr, R.R., et al. (1959–60) Antibiot. Ann. 230.
  PubMed Google Scholar
• 30Herr, R.R., et al. (1967) J. Am. Chem. Soc. 89, 4808.
  10.1021/ja00994a053

  CAS PubMed Web of Science® Google Scholar
• 31 Upjohn, (1962) US 3 027 300, US-prior. 1958.
  Google Scholar
• 32 Upjohn, (1971) US 3 577 406, US-prior. 1968.
  Google Scholar
• 33 ADIR (Servier), (1986) US 4 567 169, FR-prior. 1982.
  Google Scholar
• 34 Sankyo, (1977) US 4 003 901, JP-prior. 1971.
  Google Scholar
• 35 Tokyo Tanabe (1977) US 4 057 684, JP-prior. 1975.
  Google Scholar
• 36 Tokyo Tanabe (1979) US 4 156 777, JP-prior. 1977.
  Google Scholar
• 37Stevens, M.F.G., et al. (1984) J. Med. Chem. 27, 196.
  10.1021/jm00368a016

  CAS PubMed Web of Science® Google Scholar
• 38 Cancer Res. Campaign Technol., (1993) US 5 260 291, GB-prior. 1981.
  Google Scholar
• 39 Schering Corp., (2006) US 7 087 751, US-prior. 2001.
  Google Scholar
• 40Shealy, Y.F., et al. (1962) J. Org. Chem. 27, 2150.
  10.1021/jo01053a060

  CAS Web of Science® Google Scholar
• 41 Goodman & Gilman's, (2011) Chapter 61/II, 1690–1705.
  Google Scholar
• 42Jordheim, L.P., et al. (2013) Advances in the Development of Nucleoside and Nucleotide Analogues for Cancer and Viral Diseases, Nat. Rev. Drug Discov. 12, 447–464.
  10.1038/nrd4010

  CAS PubMed Web of Science® Google Scholar
• 43Shelton, J., et al. (2016) Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs, Chem. Rev. 116, 14379–14455.
  10.1021/acs.chemrev.6b00209

  CAS PubMed Web of Science® Google Scholar
• 44Seeger, D.R., et al. (1949) J. Am. Chem. Soc. 71, 1753.
  10.1021/ja01173a061

  CAS Web of Science® Google Scholar
• 45Waller, C.W., et al. (1948) J. Am. Chem. Soc. 70, 19.
  10.1021/ja01181a006

  CAS PubMed Web of Science® Google Scholar
• 46Piper, J.R. and Montgomery, J.A. (1974) J. Heterocyc. Chem. 11, 279.
  10.1002/jhet.5570110237

  CAS Web of Science® Google Scholar
• 47 Lederle (American Cyanamid), (1950) US 2 512 572, US-prior. 1947.
  Google Scholar
• 48Marsham, P.R., et al. (1991) J. Med. Chem. 34, 1594.
  10.1021/jm00109a011

  CAS PubMed Web of Science® Google Scholar
• 49 ICI, (1991) US 4 992 550, GB-prior. 1986.
  Google Scholar
• 50Taylor, E.C., et al. (1992) J. Med. Chem. 35, 4450.
  10.1021/jm00101a023

  CAS PubMed Web of Science® Google Scholar
• 51Taylor, E.C., et al. (2003) J. Org. Chem. 68, 9938.
  10.1021/jo030248h

  CAS PubMed Web of Science® Google Scholar
• 52 Trustees Princeton Univ., (1994) US 5 344 932, US-prior. 1989.
  Google Scholar
• 53DeGraw, J.I., et al. (1993) J. Med. Chem. 36, 2228.
  10.1021/jm00067a020

  CAS PubMed Web of Science® Google Scholar
• 54 SRI, (1994) US 5 354 751, US-prior. 1992.
  Google Scholar
• 55Elion, G.B., et al. (1952) J. Am. Chem. Soc. 74, 411.
  10.1021/ja01122a037

  CAS Web of Science® Google Scholar
• 56 Burroughs Wellcome, (1954) US 2 697 709, GB-prior. 1951.
  Google Scholar
• 57 Burroughs Wellcome, (1956) US 2 756 228, GB-prior. 1954.
  Google Scholar
• 58Elion, G.B. and Hitchings, G.H. (1955) J. Am. Chem. Soc. 77.
  Web of Science® Google Scholar
• 59 Burroughs Wellcome, (1954), US 2 697 709, GB-prior. 1951.
  Google Scholar
• 60 Burroughs Wellcome, (1959) US 2 884 667, US-prior. 1955.
  Google Scholar
• 61Christensen, L.F., et al. (1972) J. Med. Chem. 15, 735.
  10.1021/jm00277a010

  CAS PubMed Web of Science® Google Scholar
• 62Kazimerczuk, Z., et al. (1984) J. Am. Chem. Soc. 106, 6379.
  10.1021/ja00333a046

  Web of Science® Google Scholar
• 63 Ortho Pharm. Corp., (1988) US 4 760 137, US-prior. 1984.
  Google Scholar
• 64 Ortho Pharm. Corp., (1993) US 5 208 327, US-prior. 1991.
  Google Scholar
• 65Montgomery, J.A., et al. (1969) J. Med. Chem. 12, 498.
  10.1021/jm00303a605

  CAS PubMed Web of Science® Google Scholar
• 66Montgomery, J.A., et al. (1979) J. Heterocyclic Chem. 16, 157.
  10.1002/jhet.5570160129

  CAS Web of Science® Google Scholar
• 67 DoH, (1980) US 4 210 745, US-prior. 1978.
  Google Scholar
• 68 DoH, (1982) US 4 357 324, US-prior. 1981.
  Google Scholar
• 69 Schering AG (1997) US 5 602 246, US-prior. 1992.
  Google Scholar
• 70Montgomery, J.A., et al. (1992) J. Med. Chem. 35, 397.
  10.1021/jm00080a029

  CAS PubMed Web of Science® Google Scholar
• 71Bauta, W.E., et al. (2004) Org. Process. Res. Dev. 8, 889.
  10.1021/op049884n

  CAS Web of Science® Google Scholar
• 72 Sloan-Kettering Inst. Cancer Research, (1988) US 4 751 221, US-prior. 1985.
  Google Scholar
• 73 Sloan-Kettering Inst. Cancer Research, (1990) US 4 918 179, US-prior. 1985.
  Google Scholar
• 74 Ilex Products, (2004) US 6 680 382, US-prior. 2001.
  Google Scholar
• 75 Burroughs Wellcome, (1995) US 5 424 295, GB-prior. 1987.
  Google Scholar
• 76Shen, T.Y., et al. (1965) J. Org. Chem. 30, 835.
  10.1021/jo01014a043

  CAS PubMed Web of Science® Google Scholar
• 77 Upjohn, (1963) US 3 116 282, US-prior. 1956.
  Google Scholar
• 78Duschinsky, R., et al. (1957) J. Am. Chem. Soc. 79, 4559.
  10.1021/ja01573a087

  CAS Web of Science® Google Scholar
• 79 Roche, (1957) US 2 802 005, US-prior. 1956.
  Google Scholar
• 80Barton, D.H.R., et al. (1972) J. Org. Chem. 37, 329.
  10.1021/jo00967a037

  CAS PubMed Web of Science® Google Scholar
• 81Knuniants, I.L., et al. (1972) US 3 682 917, US-prior. 1970.
  Google Scholar
• 82Yasumoto, M., et al. (1977) J. Med. Chem. 20, 1592.
  10.1021/jm00222a011

  CAS PubMed Web of Science® Google Scholar
• 83Yasumoto, M., et al. (1978) J. Med. Chem. 21, 738.
  10.1021/jm00206a004

  CAS PubMed Web of Science® Google Scholar
• 84Giller, S.A., et al. (1972) US 3 635 946, US-prior. 1967.
  Google Scholar
• 85Hertel, L.W., et al. (1988) J. Org. Chem. 53, 2406.
  10.1021/jo00246a002

  CAS Web of Science® Google Scholar
• 86 Eli Lilly, (1985) US 4 526 988, US-prior. 1983.
  Google Scholar
• 87 Eli Lilly (1989) US 4 808 614, US-prior. 1983.
  Google Scholar
• 88Cook, A.F., et al. (1979) J. Med. Chem. 22, 1330.
  10.1021/jm00197a010

  CAS PubMed Web of Science® Google Scholar
• 89 Roche, (1995) US 5 472 949, EP-prior. 1992.
  Google Scholar
• 90Piskala, A. and Sorm, F. (1964) Collect. Czechoslov. Chem. Commun. 29, 2060.
  10.1135/cccc19642060

  CAS Web of Science® Google Scholar
• 91Piskala, A. and Sorm, F. (1967) US 3 350 388, US-prior. 1965.
  Google Scholar
• 92Pliml, J. and Sorm, F. (1964) Collect. Czechoslov. Chem. Commun. 29, 2576.
  10.1135/cccc19642576

  CAS Web of Science® Google Scholar
• 93Dumontet, C. and Jordan, M.A. (2010) Microtubule-Binding Agents: A Dynamic Field of Cancer Therapeutics, Nat. Rev. Drug Discov. 9, 790–803.
  10.1038/nrd3253

  CAS PubMed Web of Science® Google Scholar
• 94 Goodman & Gilman's, (2011) Microtubule-Damaging Agents, chapter 61/III, 1705–1730.
  Google Scholar
• 95Noble, R.L., et al. (1958) Ann. N. Y. Acad. Sci. 76, 882.
  10.1111/j.1749-6632.1958.tb54906.x

  CAS PubMed Web of Science® Google Scholar
• 96Gorman, M., et al. (1959) J. Am. Chem. Soc. 81 4745, 4754.
  10.1021/ja01526a075

  Web of Science® Google Scholar
• 97 Canadian Pat.&Dev., (1963) US 3 097 137, US-prior. 1958.
  Google Scholar
• 98 Eli Lilly, (1965) US 3 225 030, US-prior. 1958.
  Google Scholar
• 99 Richter Gedeon, (1978) US 4 070 358, H-prior. 1975.
  Google Scholar
• 100 Lilly, (1965) US 3 205 220, US-prior. 1961. (Extraction).
  Google Scholar
• 101 Richter Gedeon, (1975) US 3 899 493, US-prior. 1972. (Semisynthesis from vinblastine by oxidation).
  Google Scholar
• 102Burnett, C.J., et al. (1978) J. Med. Chem. 21, 88.
  10.1021/jm00199a016

  PubMed Web of Science® Google Scholar
• 103 Eli Lilly, (1980) US 4 203 898, US-prior. 1973.
  Google Scholar
• 104 Eli Lilly, (1984) US 4 479 957, US-prior. 1973.
  Google Scholar
• 105Mangeney, P., et al. (1979) J. Org. Chem. 44, 3765.
  10.1021/jo01336a006

  CAS PubMed Web of Science® Google Scholar
• 106 ANVAR, (1981) US 4 307 100, FR-prior. 1978.
  Google Scholar
• 107Raucher, S., et al. (1987) J. Am. Chem. Soc. 109, 442.
  10.1021/ja00236a023

  CAS Web of Science® Google Scholar
• 108 Lilly, (1977) US 4 029 663, US-prior. 1975.
  Google Scholar
• 109Fahy, J., et al. (1997) J. Am. Chem. Soc. 119, 8576.
  10.1021/ja971864w

  CAS Web of Science® Google Scholar
• 110 Pierre Fabre, (1997) US 5 620 985, FR-prior. 1993.
  Google Scholar
• 111Keller-Juslen, C., et al. (1971) J. Med. Chem. 14, 936.
  10.1021/jm00292a012

  CAS PubMed Web of Science® Google Scholar
• 112 Sandoz, (1970) US 3 524 844, CH-prior. 1965.
  Google Scholar
• 113Wang, Y.-F., et al. (2011) Natural Taxanes: Developments Since 1828, Chem. Rev. 111, 7652–7709.
  10.1021/cr100147u

  CAS PubMed Web of Science® Google Scholar
• 114Wani, M.C., et al. (1971) J. Am. Chem. Soc. 93, 2325.
  10.1021/ja00738a045

  CAS PubMed Web of Science® Google Scholar
• 115Denis, J.N., et al. (1988) J. Am. Chem. Soc. 110, 5917.
  10.1021/ja00225a063

  CAS Web of Science® Google Scholar
• 116Holton, R.A., et al. (1993) Bioorg. Med. Chem. Lett. 3, 2475.
  10.1016/S0960-894X(01)80981-1

  CAS Web of Science® Google Scholar
• 117 Florida State University, (1993) US 5 254 703, US-prior. 1992.
  Google Scholar
• 118Singh, A.K., et al. (2003) Org. Process. Res. Dev. 7, 25.
  10.1021/op020221k

  CAS Web of Science® Google Scholar
• 119 Phyton Biotech, (2007) US 7 264 951, US-prior. 1992.
  Google Scholar
• 120Gueritte-Voegelein, F., et al. (1992) J. Med. Chem. 34, 992.
  10.1021/jm00107a017

  PubMed Web of Science® Google Scholar
• 121 Rhone-Poulenc Rorer, (1989) US 4 814 470, FR-prior. 1986.
  Google Scholar
• 122 Rhone-Poulenc Rorer, (1988) EP 253 738, FR-prior. 1986.
  Google Scholar
• 123 Rhone Poulenc Rorer; Aventis, (1998) US 5 847 170, FR-prior. 1995.
  Google Scholar
• 124 Rhone Poulenc Rorer; Aventis (2002) US 6 387 946, FR-prior. 1995.
  Google Scholar
• 125Rinehart, K.L., et al. (1990) J. Org. Chem. 55, 4512.
  10.1021/jo00302a007

  CAS Web of Science® Google Scholar
• 126Corey, E.J., et al. (1996) J. Am. Chem. Soc. 118, 9202.
  10.1021/ja962480t

  CAS Web of Science® Google Scholar
• 127 Univ. Illinois, (1992) US 5 089 273, US-prior. 1986.
  Google Scholar
• 128 PharmaMar, (2007) US 7 202 361, GB-prior. 2000.
  Google Scholar
• 129 Merck & Co., (1945) US 2 378 876, US-prior. 1941.
  Google Scholar
• 130Arcamone, F., et al. (1975) J. Med. Chem. 18, 703.
  10.1021/jm00241a013

  CAS PubMed Web of Science® Google Scholar
• 131 Farmitalia, (1971) US 3 590 028, IT-prior. 1967.
  Google Scholar
• 132Arcamone, F., et al. (1964) J. Am. Chem. Soc. 86, 5334.
  10.1021/ja01077a059

  CAS Web of Science® Google Scholar
• 133 Farmitalia, (1977) US 4 012 284, IT-prior. 1962.
  Google Scholar
• 134Arcamone, F., et al. (1975) J. Med. Chem. 18, 703.
  10.1021/jm00241a013

  CAS PubMed Web of Science® Google Scholar
• 135 Farmitalia, (1977) US 4 058 519, IT-prior. 1974.
  Google Scholar
• 136 Farmitalia, (1977) US 4 046 878, GB-prior. 1974.
  Google Scholar
• 137 Adria Labs., (1984) US 4 471 052, US-prior. 1982.
  Google Scholar
• 138Murdock, K.C., et al. (1979) J. Med. Chem. 22, 1024.
  10.1021/jm00195a002

  CAS PubMed Web of Science® Google Scholar
• 139Zee-Cheng, R.K.-Y. and Cheng, C.C. (1978) J. Med. Chem. 21, 291.
  10.1021/jm00201a012

  CAS PubMed Web of Science® Google Scholar
• 140American Cyanamid, (1980) US 4 197 249, US-prior. 1977.
  Google Scholar
• 141 American Cyanamid, (1981) US 4 278 689, US-prior. 1978.
  Google Scholar
• 142 S.Farber Cancer Institute, (1977) US 4 035 566, US-prior. 1975.
  Google Scholar
• 143Nicolaou, K.C., et al. (1998) Chemical Biology of Epothilones, Angew. Chem. Int. Ed. 37, 2014–2045.
  10.1002/(SICI)1521-3773(19980817)37:15<2014::AID-ANIE2014>3.0.CO;2-2

  CAS PubMed Web of Science® Google Scholar
• 144Umezawa, H., et al. (1966) J. Antibiot. 19, 200; 210.
  CAS PubMed Web of Science® Google Scholar
• 145Takita, T., et al. (1968) J. Antibiot. 21, 79; (1969) J. Antibiot. 22, 237; (1972) J. Antibiot. 25, 755; (1978) J. Antibiot. 31, 801.
  10.7164/antibiotics.21.79

  CAS PubMed Web of Science® Google Scholar
• 146 Microb. Chem. Res. Found., (1980) US-RE 30 451, JP-prior. 1969.
  Google Scholar
• 147Hata, T., et al. (1956) J. Antibiot. 9A, 141.
  Google Scholar
• 148 Kyowa Hakko (1972) US 3 660 578, JP-prior. 1957.
  Google Scholar
• 149Stevens, C.L., et al. (1965) J. Med. Chem. 8, 1.
  10.1021/jm00325a001

  CAS PubMed Web of Science® Google Scholar
• 150Borzilleri, R.M., et al. (2000) J. Am. Chem. Soc. 122, 8890.
  10.1021/ja001899n

  CAS Web of Science® Google Scholar
• 151Bristol-Myers Squibb (BMS), (2003) US 6 605 599, US prior. 1997.
  Google Scholar
• 152Wilson, J.J. and Lippard, S.J. (2014) Synthetic Methods for the Preparation of Platinum Anticancer Complexes, Chem. Rev. 114, 4470–4495.
  10.1021/cr4004314

  CAS PubMed Web of Science® Google Scholar
• 153Peyrone, M. (1845) Ann. Chem. 51, 1.
  10.1002/jlac.18440510102

  Google Scholar
• 154Rosenberg, B., et al. (1965) Nature 205, 698.
  10.1038/205698a0

  CAS PubMed Web of Science® Google Scholar
• 155 MPD Technol., (1981) US 4 273 755, US-prior. 1979.
  Google Scholar
• 156 Research Corp., (1979) US 4 140 707, US-prior. 1972.
  Google Scholar
• 157Kidani, Y. and Inagaki, K. (1978) J. Med. Chem. 21, 1315.
  10.1021/jm00210a029

  CAS PubMed Web of Science® Google Scholar
• 158Kidani, Y. and Inagaki, K. (1979) US 4 169 846, JP-prior. 1976.
  Google Scholar
• 159 Roche, (1970) US 3 520 926, CH-prior. 1961.
  Google Scholar
• 160Celli, J.P., et al. (2010) Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization, Chem. Rev. 110, 2795–2838.
  10.1021/cr900300p

  CAS PubMed Web of Science® Google Scholar
• 161Lovell, J.F., et al. (2010) Activatable Photosensitizers for Imaging and Therapy, Chem. Rev. 110, 2839–2857.
  10.1021/cr900236h

  CAS PubMed Web of Science® Google Scholar
• 162 Health Research Inc., (1987) US 4 649 151, US-prior. 1982.
  Google Scholar
• 163 Univ. B.C., (1988) US 4 883 790, US-prior. 1987.
  Google Scholar
• 164 Univ. B.C. (1992) US 5 095 030, CA-prior. 1988.
  Google Scholar
• 165Quadra Logic, (1991) US 5 053 423, USA-prior. 1990.
  Google Scholar
• 166Quadra Logic, (1993) US 5 238 940, USA-prior. 1990.
  Google Scholar
• 167Siddiqui, M.A.A., et al. (2004) Am. J. Clin. Dermatol. 5, 127. (Review).
  10.2165/00128071-200405020-00006

  PubMed Web of Science® Google Scholar
• 168 Queen's Univ., (1993) US 5 234 940, US-prior. 1989.
  Google Scholar
• 169Bonnett, R., et al. (1989) Biochem. J. 261, 277.
  10.1042/bj2610277

  CAS PubMed Web of Science® Google Scholar
• 170Bonnett, R. and Martinez, G. (2002) Org. Lett. 4, 2013.
  10.1021/ol025842c

  CAS PubMed Web of Science® Google Scholar
• 171 Efamol, (1991) US 4 992 257, GB-prior. 1988.
  Google Scholar
• 172Parrish, J.A., et al. (1980) Int. J. Dermatol. 19, 379. (Use).
  10.1111/j.1365-4362.1980.tb03732.x

  CAS PubMed Web of Science® Google Scholar
• 173 US Secret. Agricult., (1959) US 2 889 337, US-prior. 1956. (Extraction).
  Google Scholar
• 174Elder, T.C. (1978) US 4 129 576, US-prior. 1976. (Synthesis).
  Google Scholar
• 175Kleemann, A. (2010) Ullmann's Chapter “Antineoplastic Agents 1”, pp. 44–49.
  Google Scholar
• 176Capdeville, R., et al. (2002) Glivec (STI 571, Imatinib), a Rationally Developed, Targeted Anticancer Drug, Nat. Rev. Drug Discov. 1, 493.
  10.1038/nrd839

  CAS PubMed Web of Science® Google Scholar
• 177Goodman & Gilman's, (2011) Chapter 62, pp. 1731–1740.
  Google Scholar
• 178Bradshaw, T.D. (2008) Target-Directed Drug Discovery, in Anticancer Therapeutics, (ed. S. Missailidis), Wiley-Blackwell, Oxford, pp. 223–243.
  10.1002/9780470697047.ch12

  Web of Science® Google Scholar
• 179Airley, R. (2009) Tyrosine Kinase Inhibitors, in Cancer Chemotherapy Chapter 14, Wiley-Blackwell, Oxford, pp. 217–223.
  Google Scholar
• 180Bridges, A.J. (2001) Chemical Inhibitors of Protein Kinases, Chem. Rev. 101, 2541–2571.
  10.1021/cr000250y

  CAS PubMed Web of Science® Google Scholar
• 181Jänne, P.A., et al. (2009) Factors Underlying Sensitivity of Cancers to Small-Molecule Kinase Inhibitors, Nat. Rev. Drug Discov. 8, 709–723.
  10.1038/nrd2871

  CAS PubMed Web of Science® Google Scholar
• 182Bikker, J.A., et al. (2009) Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies, J. Med. Chem. 52, 1493–1509.
  10.1021/jm8010542

  CAS PubMed Web of Science® Google Scholar
• 183Peták, I., et al. (2010) Integrating Molecular Diagnostics into Anticancer Drug Discovery, Nat. Rev. Drug Discov. 9, 523–535.
  10.1038/nrd3135

  CAS PubMed Web of Science® Google Scholar
• 184Morphy, R. (2010) Selectively Nonselective Kinase Inhibition: Striking the Right Balance, J. Med. Chem. (Perspective) 53, 1413–1437.
  10.1021/jm901132v

  CAS PubMed Web of Science® Google Scholar
• 185Davis, M.I., et al. (2011) Comprehensive Analysis of Kinase Inhibitor Selectivity, Nat. Biotechnol. 29, 1046–1052.
  10.1038/nbt.1990

  CAS PubMed Web of Science® Google Scholar
• 186Barf, T. and Kaptein, A. (2012) Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks, J. Med. Chem. 55, 6243–6262.
  10.1021/jm3003203

  CAS PubMed Web of Science® Google Scholar
• 187Musumeci, F., et al. (2012) Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors, J. Med. Chem. 55, 10797–10822.
  10.1021/jm301085w

  CAS PubMed Web of Science® Google Scholar
• 188Cui, J.J. (2014) A New Challenging and Promising Era of Tyrosine Kinase Inhibitors, ACS Med. Chem. Lett. 5, 272–274.
  10.1021/ml500091p

  CAS PubMed Web of Science® Google Scholar
• 189Fruman, D.A. and Rommel, C. (2014) P13K and Cancer: Lessons, Challenges and Opportunities, Nat. Rev. Drug Discov. 13, 140–156.
  10.1038/nrd4204

  CAS PubMed Web of Science® Google Scholar
• 190 Various Authors (2015) J. Med. Chem. 58, 1–521. special issue “New frontiers in Kinases”.
  10.1021/jm5018708

  CAS PubMed Web of Science® Google Scholar
• 191Asghar, U., et al. (2015) The History and Future of Targeting Cyclin-Dependent Kinases (CDKs) in Cancer Therapy, Nat. Rev. Drug Discov. 14, 130–146.
  10.1038/nrd4504

  CAS PubMed Web of Science® Google Scholar
• 192Myers, S.H., et al. (2016) AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective, J. Med. Chem. 59, 3593–3608.
  10.1021/acs.jmedchem.5b01273

  CAS PubMed Web of Science® Google Scholar
• 193Cohen, P. and Alessi, D.R. (2013) Kinase Drug Discovery – What's Next in the Field? ACS Chem. Biol. 8, 96–104.
  10.1021/cb300610s

  CAS PubMed Web of Science® Google Scholar
• 194Zimmermann, J., et al. (1997) Bioorg. Med. Chem. Lett. 7, 187.
  10.1016/S0960-894X(96)00601-4

  CAS Web of Science® Google Scholar
• 195Capdeville, R., et al. (2002) Nat. Rev. Drug Discov. 1, 493.
  10.1038/nrd839

  CAS PubMed Web of Science® Google Scholar
• 196Ciba-Geigy, (1996) US 5 521 184, US-prior. 1993.
  Google Scholar
• 197Barker, A.J., et al. (2001) Bioorg. Med. Chem. Lett. 11, 1911.
  10.1016/S0960-894X(01)00344-4

  CAS PubMed Web of Science® Google Scholar
• 198Zeneca, (1998) US 5 770 599, GB-prior. 1995.
  Google Scholar
• 199Pfizer, (1998) US 5 747 498, US-prior. 1996.
  Google Scholar
• 200Dowell, J., et al. (2005) Nat. Rev. Drug Discov. 4, 13.
  10.1038/nrd1612

  CAS PubMed Web of Science® Google Scholar
• 201Sun, L., et al. (2003) J. Med. Chem. 46, 1116.
  10.1021/jm0204183

  CAS PubMed Web of Science® Google Scholar
• 202Manley, J.M., et al. (2003) J. Org. Chem. 68, 6447.
  10.1021/jo034304q

  CAS PubMed Web of Science® Google Scholar
• 203Atkins, M., et al. (2006) Nat. Rev. Drug Discov. 5, 279.
  10.1038/nrd2012

  CAS PubMed Web of Science® Google Scholar
• 204Sugen, (1998) US 5 792 783, US-prior. 1995.
  Google Scholar
• 205Bankston, D., et al. (2002) Org. Process. Res. Dev. 6, 777.
  10.1021/op020205n

  CAS Web of Science® Google Scholar
• 206Wilhelm, S., et al. (2006) Nat. Rev. Drug Discov. 5, 835.
  10.1038/nrd2130

  CAS PubMed Web of Science® Google Scholar
• 207Bayer, (2007) US 7 235 576, US-prior. 2001.
  Google Scholar
• 208Bayer, (2008) US 7 351 834, US-prior. 1999.
  Google Scholar
• 209Lombardo, L.J., et al. (2004) J. Med. Chem. 47, 6658.
  10.1021/jm049486a

  CAS PubMed Web of Science® Google Scholar
• 210Kantarjian, H., et al. (2006) Nat. Rev. Drug Discov. 5, 717.
  10.1038/nrd2135

  CAS PubMed Web of Science® Google Scholar
• 211 Bristol-Myers Squibb, (2003) US 6 596 746, US-prior. 1999.
  Google Scholar
• 212Moy, B., et al. (2007) Nature Rev, Drug Discov. 6, 431.
  10.1038/nrd2332

  CAS Google Scholar
• 213SmithKline Beecham; GlaxoSmithKline, (2006) US 7 109 333, GB-prior. 1998.
  Google Scholar
• 214Quintás-Cardama, A., et al. (2007) Nat. Rev. Drug Discov. 6, 834.
  10.1038/nrd2324

  CAS PubMed Web of Science® Google Scholar
• 215Storey, S. (2009) Nat. Rev. Drug Discov. 8, 447.
  10.1038/nrd2873

  CAS PubMed Web of Science® Google Scholar
• 216Novartis, (2007) US 7 169 791, GB-prior. 2002.
  Google Scholar
• 217AHP, (1994) US 5 362 718, US-prior. 1994.
  Google Scholar
• 218Wyeth, (2001) US 6 277 983, US-prior. 2000.
  Google Scholar
• 219Sandoz, (1997) US 5 665 772, GB-prior. 1992.
  Google Scholar
• 220American Home Products, (2001) US 6 277 983, US prior. 2000.
  Google Scholar
• 221Bukowski, R.M., et al. (2010) Nat. Rev. Drug Discov. 9, 17.
  10.1038/nrd3073

  CAS PubMed Web of Science® Google Scholar
• 222Harris, P.A., et al. (2008) J. Med. Chem. 51, 4632.
  10.1021/jm800566m

  CAS PubMed Web of Science® Google Scholar
• 223SKB, (2006) US 7 105 530, US-prior. 2000.
  Google Scholar
• 224SKB, (2007) US 7 262 203, US-prior. 2000.
  Google Scholar
• 225GSK, (2012) US 8 114 885, US-prior. 2000.
  Google Scholar
• 226Hennequin, L.F., et al. (2002) J. Med. Chem. 45, 1300.
  10.1021/jm011022e

  CAS PubMed Web of Science® Google Scholar
• 227AstraZeneca, (2007) US 7 173 038, EP-prior. 1999.
  Google Scholar
• 228Boehringer Ing, (2012) US RE 43 431, DE-prior. 2000.
  Google Scholar
• 229Boehringer Ing, (2006) US 7 019 012, DE-prior. 2000.
  Google Scholar
• 230Boschelli, D.H., et al. (2001) J. Med. Chem. 44, 3965. (2004) J. Med. Chem 47, 1599.
  10.1021/jm0102250

  CAS PubMed Web of Science® Google Scholar
• 231American Cyanamid, (1999) US 6 002 008, US-prior. 1997.
  Google Scholar
• 232Bollag, G., et al. (2010) Nature 467, 596.
  10.1038/nature09454

  CAS PubMed Web of Science® Google Scholar
• 233Bollag, G., et al. (2012) Nat. Rev. Drug Discov. 11, 873.
  10.1038/nrd3847

  CAS PubMed Web of Science® Google Scholar
• 234Plexxikon, (2011) US 7 863 288, USA-prior. 2005 [661 pages]
  Google Scholar
• 235Plexxikon (27.03.2012) US 8 143 271; USA-prior. 22.06.2005 [670 pages]
  Google Scholar
• 236Shaw, A.T., et al. (2011) Nat. Rev. Drug Discov. 10, 897.
  10.1038/nrd3600

  CAS PubMed Web of Science® Google Scholar
• 237Cui, J.J., et al. (2011) J. Med. Chem. 54, 6342.
  10.1021/jm2007613

  CAS PubMed Web of Science® Google Scholar
• 238Agouron, (2010) US 7 858 643, US-prior. 2004.
  Google Scholar
• 239de Koning, P.P., et al. (2011) Org. Process. Res. Dev. 15, 1018.
  10.1021/op200131n

  CAS Web of Science® Google Scholar
• 240Agouron, (2001) US 6 534 524, US-prior. 1999.
  Google Scholar
• 241Agouron, (2007) US 7 232 910, US-prior. 2004.
  Google Scholar
• 242Xiang, Y., et al. (2008) Org. Process. Res. Dev. 12, 116.
  10.1021/op700227p

  CAS Web of Science® Google Scholar
• 243Flahive, E.J., et al. (2008) Org. Process. Res. Dev. 12, 637.
  10.1021/op600280g

  CAS Web of Science® Google Scholar
• 244Chekal, B.P., et al. (2009) Org. Process. Res. Dev. 13, 1327.
  10.1021/op9001559

  CAS Web of Science® Google Scholar
• 245Mesa, R.A., et al. (2012) Nat. Rev. Drug Discov. 11, 103.
  10.1038/nrd3652

  CAS PubMed Web of Science® Google Scholar
• 246Moran, N. (2012) Nat. Biotechnol. 30, 3.
  10.1038/nbt0112-3

  CAS PubMed Web of Science® Google Scholar
• 247Incyte, (2009) US 7 598 257, US-prior. 2005.
  Google Scholar
• 248Bayer, (2005) WO 2005/009961, US-prior. 2003.
  Google Scholar
• 249Bayer, (2008) US 7 351 834, US-prior. 1999.
  Google Scholar
• 250Bankston, D., et al. (2002) Org. Process. Res. Dev. 6, 777.
  10.1021/op020205n

  CAS Web of Science® Google Scholar
• 251Rheault, T.R., et al. (2013) Med. Chem. Lett. 4, 358.
  10.1021/ml4000063

  CAS Web of Science® Google Scholar
• 252GSK, (2011) US 7 994 185, US-prior. 2008.
  Google Scholar
• 253GSK, (2013) US 8 415 345, US-prior. 2011.
  Google Scholar
• 254Huang, W.-S., et al. (2010) J. Med. Chem. 53, 4701.
  10.1021/jm100395q

  CAS PubMed Web of Science® Google Scholar
• 255Ariad Pharmaceuticals, (2012) US 8 114 874, US-prior. 2006.
  Google Scholar
• 256Abe, H., et al. (2011) Med. Chem. Lett. 2, 320.
  10.1021/ml200004g

  CAS Web of Science® Google Scholar
• 257Japan Tobacco, (2013) US 7 378 423, JP-prior. 2004.
  Google Scholar
• 258Exelixis, (2009) US 7 579 473, US-prior. 2003.
  Google Scholar
• 259Exelixis, (2012) US 8 178 532, US-prior. 2004.
  Google Scholar
• 260Young, R.M., et al. (2013) Nat. Rev. Drug Discov. 12, 229.
  10.1038/nrd3937

  CAS PubMed Web of Science® Google Scholar
• 261Pharmacyclics, (2009) US 7 514 444, US-prior. 2006.
  Google Scholar
• 262Pharmacyclics, (2013) US 8 399 470, US-prior. 2006.
  Google Scholar
• 263Chen, J., et al. (2013) J. Med. Chem. 56, 5673.
  10.1021/jm401005u

  CAS PubMed Web of Science® Google Scholar
• 264Marsilje, T.H., et al. (2013) J. Med. Chem. 56, 5675.
  10.1021/jm400402q

  CAS PubMed Web of Science® Google Scholar
• 265Novartis, (2011) US 7 893 074, GB-prior. 2003.
  Google Scholar
• 266Novartis, (2011) US 7 964 592, GB-prior. 2003.
  Google Scholar
• 267Cully, M. (2015) Nat. Rev. Drug Discov. 14, 229.
  10.1038/nrd4599

  CAS PubMed Web of Science® Google Scholar
• 268Eisai, (2007) US 7 253 286, JP-prior. 2000.
  Google Scholar
• 269Eisai, (2009) US 7 612 208, JP-prior. 2003.
  Google Scholar
• 270Roth, G.J., et al. (2009) J. Med. Chem. 52, 4466.
  10.1021/jm900431g

  CAS PubMed Web of Science® Google Scholar
• 271Roth, G.J., et al. (2015) J. Med. Chem. 58, 1053.
  10.1021/jm501562a

  CAS PubMed Web of Science® Google Scholar
• 272Boehringer Ing, (2003) US 6 762 180, DE-prior. 1999.
  Google Scholar
• 273VanderWel, S.N., et al. (2005) J. Med. Chem. 48, 2371.
  10.1021/jm049355+

  CAS PubMed Web of Science® Google Scholar
• 274Toogood, P.L., et al. (2005) J. Med. Chem. 48, 2388.
  10.1021/jm049354h

  CAS PubMed Web of Science® Google Scholar
• 275Maloney, M.T., et al. (2016) Org. Process Res. Dev. 20, 1191, 1203, 1217. (Commercial Process).
  10.1021/acs.oprd.6b00069

  Web of Science® Google Scholar
• 276Warner-Lambert, (2005) US 6 936 612, USA-prior. 2002.
  Google Scholar
• 277Pfizer, (2010) US 7 781 583, USA-prior. 2006.
  Google Scholar
• 278Finlay, M.R.V., et al. (2014) J. Med. Chem. 57, 8249–8267. (Synthesis).
  10.1021/jm500973a

  CAS PubMed Web of Science® Google Scholar
• 279AstraZeneca, (2013) WO 2013/014448, USA-prior. 2011.
  Google Scholar
• 280AstraZeneca, (2015) US 8 946 235, USA-prior. 2011.
  Google Scholar
• 281Kinoshita, K., et al. (2012) Bioorg. Med. Chem. 20, 1271.
  10.1016/j.bmc.2011.12.021

  CAS PubMed Web of Science® Google Scholar
• 282Chugai, (2015) US 9 126 931JP-prior. 2009.
  Google Scholar
• 283Chugai, (2016) US 9 365 514, JP-prior. 2010.
  Google Scholar
• 284Rice, K.D., et al. (2012) Med. Chem. Lett. 3, 416–421. (Synthesis).
  10.1021/ml300049d

  CAS Web of Science® Google Scholar
• 285Exelixis, (2010) US 7 803 839, USA-prior. 2005.
  Google Scholar
• 286Exelixis, (2013) US 8 362 002, USA-prior. 2005.
  Google Scholar
• 287Paris, M., et al. (2008) Histone Deacetylase (HDAC) Inhibitors: From Bench to Clinic, J. Med. Chem. 51, 1505–1529. [incl. Vorinostat, Romidepsin, Panobinostat, Belinostat].
  10.1021/jm7011408

  CAS PubMed Web of Science® Google Scholar
• 288Rentsch, A., et al. (2013) Synthesis and Pharmacology of Proteasome Inhibitors, Angew. Chem. Internat. Ed. 52, 5450–5488. [incl. Bortezomib, Carfilzomib, Ixazomib].
  10.1002/anie.201207900

  CAS PubMed Web of Science® Google Scholar
• 289Jackson, K.L., et al. (2009) The Halichondrins and E7389, Chem. Rev. 109, 3044–3079. [Eribulin].
  10.1021/cr900016w

  CAS PubMed Web of Science® Google Scholar
• 290Cain, B.F., et al. (1975) J. Med. Chem. 18, 1110.
  10.1021/jm00245a013

  CAS PubMed Web of Science® Google Scholar
• 291Hofmann, A.W. (1885) Berkut 18, 2755.
  10.1002/cber.188501802188

  Google Scholar
• 292Cassella, (1969) US 3 424 752 DE-prior. 1965.
  Google Scholar
• 293Dressler, W.F.C., et al. (1869) Annalen 150, 242.
  10.1002/jlac.18691500212

  Google Scholar
• 294Du Pont, (1955) US 2 705 727 US-prior. 1952.
  Google Scholar
• 295Woo, P.W.K., et al. (1974) J. Heterocyclic Chem. 11, 641.
  10.1002/jhet.5570110438

  CAS Web of Science® Google Scholar
• 296Parke Davis, (1975) US 3 923 785, US-prior. 1974.
  Google Scholar
• 297Warner-Lambert, (1995) US 5 463 035 US-prior. 1991.
  Google Scholar
• 298 ASTA Medica, (1997) EP 521 297, DE-prior. 1991.
  Google Scholar
• 299MPG, (1989) US 4 837 023, DE-prior. 1985 and 1986.
  Google Scholar
• 300Leo, (1977) US Re 29199, GB-prior. 1963. [reissue of US 3 299 104]
  Google Scholar
• 301 Roche, (1973) US 3 746 730, CH-prior. 1969.
  Google Scholar
• 302Kingsbury, W.D., et al. (1991) J. Med. Chem. 34, 98.
  10.1021/jm00105a017

  CAS PubMed Web of Science® Google Scholar
• 303SmithKline Beecham, (1991) US 5 004 758, US-prior. 1987.
  Google Scholar
• 304Sawada, S., et al. (1986) Chem. Pharm. Bull. 39, 1446.
  10.1248/cpb.39.1446

  Google Scholar
• 305Yakult Honsha, (1986) US 4 604 463, JP-prior. 1983.
  Google Scholar
• 306Robeson, C.D., et al. (1955) J. Am. Chem. Soc. 77, 4111.
  10.1021/ja01620a043

  CAS Web of Science® Google Scholar
• 307Boehm, M.F., et al. (1994) J. Med. Chem. 37, 408.
  10.1021/jm00029a013

  CAS PubMed Web of Science® Google Scholar
• 308Bennani, Y.L. (1996) J. Org. Chem. 61, 3542.
  10.1021/jo952189g

  CAS Web of Science® Google Scholar
• 309Terzolo, M., et al. (2007) N. Engl. J. Med. 356, 2372.
  10.1056/NEJMoa063360

  CAS PubMed Web of Science® Google Scholar
• 310Hailer, B.L., et al. (1945) J. Am. Chem. Soc. 67, 1591. (Synthesis).
  10.1021/ja01225a058

  Web of Science® Google Scholar
• 311Soignet, S.L., et al. (1998) N. Engl. J. Med. 339, 1341.
  10.1056/NEJM199811053391901

  CAS PubMed Web of Science® Google Scholar
• 312Miller, W.H., et al. (2002) Cancer Res. 62, 3893.
  CAS PubMed Web of Science® Google Scholar
• 313Memorial Sloan Kettering Cancer Center, (2004) US 6 723 351, US-prior. 1997.
  Google Scholar
• 314Boehm, M.F., et al. (1994) J. Med. Chem. 37, 2930.
  10.1021/jm00044a014

  CAS PubMed Web of Science® Google Scholar
• 315Ligand Pharmac., (1998) US 5 780 676, US-prior. 1992.
  Google Scholar
• 316Adams, J., et al. (1998) Bioorg. Med. Chem. Lett. 8, 333.
  10.1016/S0960-894X(98)00029-8

  CAS PubMed Web of Science® Google Scholar
• 317Millennium Pharmac, (1998) US 5 780 454, US-prior. 1994.
  Google Scholar
• 318Millennium Pharmac, (2004) US 6 747 150, US-prior. 1994.
  Google Scholar
• 319Yamaguchi, H., et al. (1981) J. Heterocyc. Chem. 18, 67.
  10.1002/jhet.5570180114

  CAS Web of Science® Google Scholar
• 320Roberts Lab., (1996) EP 778 258 US-prior. 1995.
  Google Scholar
• 321Bristol-Myers, (1976) US 3 932 407 US-prior. 1972.
  Google Scholar
• 322Stowell, J.C., et al. (1995) J. Med. Chem. 38, 1411.
  10.1021/jm00008a020

  CAS PubMed Web of Science® Google Scholar
• 323Sloan-Kettering Inst. Cancer Res., (1994) US 5 369 108, US-prior. 1991.
  Google Scholar
• 324Okuhara, M., et al. (1994) J. Antibiot. 47, 301.
  10.7164/antibiotics.47.301

  PubMed Web of Science® Google Scholar
• 325 Fujisawa, (1990) US 4 977 138, GB-prior. 1988.
  Google Scholar
• 326ChemGenex, (2009) US 2009/0176759, US-prior. 2007.
  Google Scholar
• 327Stragen, (2007) US 7 169 774 FR-prior. 1998.
  Google Scholar
• 328Zheng, W., et al. (2004) Bioorg. Med. Chem. Lett. 14, 5551.
  10.1016/j.bmcl.2004.08.069

  CAS PubMed Web of Science® Google Scholar
• 329Eisai, (2001) US 6 214 865, US-prior. 1998.
  Google Scholar
• 330Eisai, (2008) US 7 470 720, US-prior. 2002.
  Google Scholar
• 331Guha, M. (2015) Nat. Rev. Drug Discov. 14, 225.
  10.1038/nrd4583

  CAS PubMed Web of Science® Google Scholar
• 332Novartis, (2003) US 6 552 065, USA-prior. 2000.
  Google Scholar
• 333Novartis, (2014) US 8 883 842, USA-prior. 2005. (Medical use in multiple myeloma).
  Google Scholar
• 334Gianetti, A.M., et al. (2011) J. Med. Chem. 54 (8), 2592.
  10.1021/jm1008924

  CAS PubMed Web of Science® Google Scholar
• 335Curis, (2011) US 7 888 364, USA-prior. 2004.
  Google Scholar
• 336Zhou, H.J., et al. (2009) J. Med. Chem. 52, 3028.
  10.1021/jm801329v

  CAS PubMed Web of Science® Google Scholar
• 337Proteolix, (2007) US 7 232 818, USA-prior. 2004.
  Google Scholar
• 338Menear, K.A., et al. (2008) J. Med. Chem. 51, 6581.
  10.1021/jm8001263

  CAS PubMed Web of Science® Google Scholar
• 339Kudos, (2006) US 7 151 102, GB-prior. 2000.
  Google Scholar
• 340Kudos, (2012) US 8 183 369, USA-prior. 2007.
  Google Scholar
• 341Patel, L., et al. (2016) J. Med. Chem. 59, 3532.
  10.1021/acs.jmedchem.6b00213

  CAS PubMed Web of Science® Google Scholar
• 342 ICOS, (2004) US 6 800 620, USA-prior. 2000.
  Google Scholar
• 343 ICOS, (2011) US 7 932 260 USA-prior. 2004.
  Google Scholar
• 344 ICOS, (2013) US RE 44 599 USA-prior. 2004.
  Google Scholar
• 345 ICOS, (2013) US RE 44 638 USA-prior. 2004.
  Google Scholar
• 346Pan, S., et al. (2010) ACS Med. Chem. Lett. 1, 130.
  10.1021/ml1000307

  CAS PubMed Web of Science® Google Scholar
• 347Novartis, (2011) US 8 063 043, USA-prior. 2008.
  Google Scholar
• 348IRM LLC, (2012) US 8 178 563, USA-prior. 2006.
  Google Scholar
• 349Topo Target, (2005) US 6 888 027, GB-prior. 2000.
  Google Scholar
• 350Formulation: Topo Target, (2014) US 8 835 501, USA-prior. 2005. (Formulation).
  Google Scholar
• 351Chizkov, R.R. and Million, R.P. (2015) Nat. Rev. Drug Discov. 14, 597.
  10.1038/nrd4717

  CAS PubMed Web of Science® Google Scholar
• 352Millenium Pharm., (2008) US 7 442 830, USA prior. 2007.
  Google Scholar
• 353Millenium Pharm., (2013) US 8 530 694, USA-prior. 2007.
  Google Scholar
• 354Bruncko, M., et al. (2007) J. Med. Chem. 50, 641–662. (Synthesis).
  10.1021/jm061152t

  CAS PubMed Web of Science® Google Scholar
• 355Abbvie, (2013) US 8 546 399, US-prior. 2009 – see ex.1, pp. 107–112.
  Google Scholar
• 356Goodman & Gilman's, (2011) Chapter 63, pp. 1755–1769.
  Google Scholar
• 357Airley, R. (2009) Cancer Chemotherapy, Wiley-Blackwell, Chichester, p. 106 ff.
  Google Scholar
• 358Sneader, W. (2005) Drug Discovery–A History, J. Wiley & Sons, Chichester, p. 195 ff.
  10.1002/0470015535

  Google Scholar
• 359Fernö, O., et al. (1958) Acta Chem. Scand. 12, 1675.
  10.3891/acta.chem.scand.12-1675

  CAS Web of Science® Google Scholar
• 360AB Leo, (1960) US 2 928 849, DK-prior. 1953.
  Google Scholar
• 361Inhoffen, H.H., et al. (1938) Ber. Dtsch. Chem. Ges. 71, 1024.
  10.1002/cber.19380710520

  Web of Science® Google Scholar
• 362Inhoffen, H.H., et al. (1938) Naturwissenschaften 26, 96.
  10.1007/BF01681040

  CAS Web of Science® Google Scholar
• 363 Schering, (1941) US 2 243 887, DE-prior. 1935.
  Google Scholar
• 364 Schering, (1941) US 2 251 939, FR-prior. 1935.
  Google Scholar
• 365 Schering, (1941) US 2 265 976, DE-prior. 1937.
  Google Scholar
• 366 Ciba, (1941) US 2 267 257, CH-prior. 1937.
  Google Scholar
• 367Ringold, H.J., et al. (1959) J. Am. Chem. Soc. 81, 3712.
  10.1021/ja01523a055

  CAS Web of Science® Google Scholar
• 368 Searle, (1959) US 2 891 079, US-prior. 1959.
  Google Scholar
• 369Babcock, J.C., et al. (1958) J. Am. Chem. Soc. 80, 2904.
  10.1021/ja01544a079

  CAS Web of Science® Google Scholar
• 370Ellis, B., et al. (1957) J. Chem. Soc. 4092.
  Web of Science® Google Scholar
• 371 Upjohn, (1964) US 3 147 290, US-prior. 1956.
  Google Scholar
• 372 Syntex, (1958) DE 1 097 986, MX-prior. 1956.
  Google Scholar
• 373 Hoechst, (1977) US 4 024 248, DE-prior. 1974.
  Google Scholar
• 374Dutta, A.S., et al. (1978) J. Med. Chem. 21, 1018.
  10.1021/jm00208a004

  CAS PubMed Web of Science® Google Scholar
• 375 Abbott, (1977) US 3 914 412, US-prior. 1973.
  Google Scholar
• 376 Takeda, (1976) GB 1 434 694, GB-prior. 1973.
  Google Scholar
• 377Dutta, A.S., et al. (1978) J. Med. Chem. 21, 1018.
  10.1021/jm00208a004

  CAS PubMed Web of Science® Google Scholar
• 378 ICI/AstraZeneca, (1977) US 4 100 274, GB-prior. 1976.
  Google Scholar
• 379Coy, D.H., et al. (1976) J. Med. Chem. 19, 423.
  10.1021/jm00225a018

  CAS PubMed Web of Science® Google Scholar
• 380Schally, A.V. and Coy, D.H. (1977) US 4 010 125, US-prior. 1975.
  Google Scholar
• 381Debiopharm, (1993) US 5 225 205, CH-prior. 1989. (Pamoate microparticles).
  Google Scholar
• 382Rivier, J.E.F., et al. (1978) Life Sci. 23, 869.
  10.1016/0024-3205(78)90522-2

  CAS PubMed Web of Science® Google Scholar
• 383 Salk Institute, (1981) US 4 244 946, US-prior. 1979.
  Google Scholar
• 384Harper, M.J.K., et al. (1966) Nature 212, 87.
  10.1038/212087a0

  CAS PubMed Web of Science® Google Scholar
• 385 ICI, (1985) US 4 536 516, GB-prior. 1962, 1965.
  Google Scholar
• 386 Farmos, (1983) US 4 696 949, GB-prior. 1982.
  Google Scholar
• 387 ICI, (1987) US 4 659 516, GB-prior. 1983.
  Google Scholar
• 388Baker, J.W., et al. (1967) J. Med. Chem. 10, 93.
  10.1021/jm00313a020

  CAS PubMed Web of Science® Google Scholar
• 389Schering Corpor., (1974) US 3 847 988, US-prior. 1971.
  Google Scholar
• 390Roussel-Uclaf, (1976) US 4 097 578, FR-prior. 1975.
  Google Scholar
• 391Tucker, H., et al. (1988) J. Med. Chem. 31, 954.
  10.1021/jm00400a011

  CAS PubMed Web of Science® Google Scholar
• 392 ICI/AstraZeneca, (1987) US 4 636 505, GB-prior. 1982.
  Google Scholar
• 393Tran, C., et al. (2009) Science 324, 787.
  10.1126/science.1168175

  CAS PubMed Web of Science® Google Scholar
• 394Jung, M.E., et al. (2010) J. Med. Chem. 53, 2779.
  10.1021/jm901488g

  CAS PubMed Web of Science® Google Scholar
• 395Univ. California, (2010) US 7 709 517, USA-prior. 2005.
  Google Scholar
• 396Univ. California, (2012) US 8 183 274, USA-prior. 2005.
  Google Scholar
• 397 Ciba, (1958) US 2 848 455, CH-prior. 1955.
  Google Scholar
• 398 ICI/AstraZeneca, (1990) US 4 935 437, GB-prior. 1987.
  Google Scholar
• 399Ciba-Geigy/Novartis, (1990) US 4 978 672, US-prior. 1986.
  Google Scholar
• 400 Farmitalia, (1989) US 4 808 616, GB-prior. 1985.
  Google Scholar
• 401Indiana Univ., (1998) US 5 843 901, US-prior. 1995.
  Google Scholar
• 402Samant, M.P., et al. (2006) J. Med. Chem. 49, 3536.
  10.1021/jm060240a

  CAS PubMed Web of Science® Google Scholar
• 403Jiang, G., et al. (2001) J. Med. Chem. 44, 453.
  10.1021/jm0003900

  CAS PubMed Web of Science® Google Scholar
• 404Ferring, (1999) US 5 925 730, US-prior. 1997.
  Google Scholar
• 405Potter, G.A., et al. (1995) J. Med. Chem. 38, 2463.
  10.1021/jm00013a022

  CAS PubMed Web of Science® Google Scholar
• 406Potter, G.A., et al. (1997) Org. Prep. Proced. Int. 29, 123.
  10.1080/00304949709355175

  CAS Web of Science® Google Scholar
• 407British Technol. Group, (1997) US 5 604 213, GB-prior. 1992.
  Google Scholar
• 408 Syntex, (1988) US 4 753 935, US-prior. 1987.
  Google Scholar
• 409Williams, R.H., et al. (1968) J. Antibiot. 21, 463.
  10.7164/antibiotics.21.463

  CAS PubMed Web of Science® Google Scholar
• 410Suzuki, S., et al. (1969) J. Antibiot. 22, 297.
  10.7164/antibiotics.22.297

  CAS PubMed Web of Science® Google Scholar
• 411ICI, (1967) GB 1 157 099, GB-prior. 1966. (Fermentation).
  Google Scholar
• 412Vézina, C., et al. (1975) J. Antibiot. 28, 721.
  10.7164/antibiotics.28.721

  CAS PubMed Web of Science® Google Scholar
• 413Sehgal, S.N., et al. (1975) J. Antibiot. 28, 727.
  10.7164/antibiotics.28.727

  CAS PubMed Web of Science® Google Scholar
• 414 Ayerst, (1975) US 3 929 992, US-prior. 1972.
  Google Scholar
• 415 Hoechst, (1978) US 4 087 535, DE-prior. 1975.
  Google Scholar
• 416 Hoechst, (1981) US 4 284 786, DE-prior. 1978.
  Google Scholar
• 417Adachi, K., et al. (1995) Bioorg. Med. Chem. Lett. 5 (847), 853.
  10.1016/0960-894X(95)00127-F

  CAS Web of Science® Google Scholar
• 418Kiuchi, M., et al. (2000) J. Med. Chem. 43, 2946.
  10.1021/jm000173z

  CAS PubMed Web of Science® Google Scholar
• 419Yoshitomi, (1997) US 5 604 229, JP-prior. 1992, 1993.
  Google Scholar
• 420Flanagan, M.E., et al. (2010) J. Med. Chem. 53, 8468–8484. (Synthesis).
  10.1021/jm1004286

  CAS PubMed Web of Science® Google Scholar
• 421Pfizer, (2007) US 7 265 221, USA-prior. 1999.
  Google Scholar
• 422Pfizer, (2010) US RE 41783, USA-prior. 1999.
  Google Scholar
• 423Pfizer, (2007) US 7 301 023, USA-prior. 2001.
  Google Scholar
• 424Rüegger, A., et al. (1976) Helv. Chim. Acta 59, 1075.
  10.1002/hlca.19760590412

  CAS PubMed Web of Science® Google Scholar
• 425 Sandoz, (1978) US 4 117 118, CH-prior. 1974.
  Google Scholar
• 426Kino, T., et al. (1987) J. Antibiot. 40, 1249.
  10.7164/antibiotics.40.1249

  CAS PubMed Web of Science® Google Scholar
• 427 Fujisawa, (1986) EP 184 162, GB-prior. 1985.
  Google Scholar
• 428Synthesis: Fujisawa, (1990) EP 378 318, US-prior. 1989.
  Google Scholar
• 429Folkman, J. (2007) Angiogenesis: An Organizing Principle for Drug Discovery? Nat. Rev. Drug Discov. 6, 273–286. [Thalidomide, Lenalidomide, Pomalidomide].
  10.1038/nrd2115

  CAS PubMed Web of Science® Google Scholar
• 430Burroughs Wellcome, (1962) US 3 056 785, US-prior. 1960.
  Google Scholar
• 431 Grünenthal, (1957) GB 768 821, DE-prior. 1954.
  Google Scholar
• 432Muller, G.W., et al. (1999) Bioorg. Med. Chem. Lett. 9, 1625.
  10.1016/S0960-894X(99)00250-4

  CAS PubMed Web of Science® Google Scholar
• 433Celgene, (1997) US 5 635 517, US-prior. 1996.
  Google Scholar
• 434Affil. Medical Res., (1974) US 3 839 346, US-prior. 1972.
  Google Scholar
• 435Margolin, S.B. (2002) EP 702 551 US-prior. 1993.
  Google Scholar
• 436Stewart, A.K. (2014) Science 343, 256.
  10.1126/science.1249543

  CAS PubMed Web of Science® Google Scholar
• 437Winter, G.E., et al. (2015) Science 348, 1376.
  10.1126/science.aab1433

  CAS PubMed Web of Science® Google Scholar
• 438Celgene, (1997) US 5 635 517, USA-prior. 1996.
  Google Scholar
• 439Celgene, (2002) US 6 335 349, USA-prior. 1996.
  Google Scholar
• 440Hoffer, M., et al. (1959) J. Am. Chem. Soc. 81, 4112.
  10.1021/ja01524a079

  CAS Web of Science® Google Scholar
• 441Heidelberger, Ch., Duschinsky, R. (1959) US 2 885 396, USA-prior.1957.
  Google Scholar
• 442Heidelberger, Ch., Duschinsky, R. (1961), US 2 970 139, USA-prior. 1958.
  Google Scholar
• 443Roche, (1960) US 2 949 451, USA-prior. 1959.
  Google Scholar
• 444Roche, (1962) US 3 041 335, USA-prior. 1959.
  Google Scholar
• 445Chon Kun Dang, (2001) US 6 310 207, KR-prior. 1997.
  Google Scholar
• 446Ishizumi, K., et al. (1987) J. Org. Chem. 52, 4477.
  10.1021/jo00229a010

  CAS Web of Science® Google Scholar
• 447Sumitomo, (1985) US 4 540 695, JP-prior. 1981.
  Google Scholar
• 448Sumitomo, (1987) US 4 673 668, JP-prior. 1982.
  Google Scholar
• 449Smaill, J.B., et al. (2016) J. Med. Chem. 59, 8103–8124.
  10.1021/acs.jmedchem.6b00883

  CAS PubMed Web of Science® Google Scholar
• 450Pfizer, Warner Lambert, (2010) US 7 772 243; USA-prior. 2005.
  Google Scholar
• 451Betta Pharmaceuticals, (2015) US 9 085 588, PCT-prior. 2012.
  Google Scholar
• 452Novartis, (2013) US 8 501 758, USA-prior. 2009.
  Google Scholar
• 453Array Bio Pharma, (2017), US 9 850 230, USA-prior. 2009.
  Google Scholar
• 454Huang, W.S., et al. (2016) J. Med. Chem. 59, 4948–4964.
  10.1021/acs.jmedchem.6b00306

  CAS PubMed Web of Science® Google Scholar
• 455Ariad, (2015), US 9 012 462, USA-prior. 2008.
  Google Scholar
• 456Ariad, (2017), US 9 611 283, USA-prior. 2013.
  Google Scholar
• 457Johnson, T.W., et al. (2014) J. Med. Chem. 57, 4720.
  10.1021/jm500261q

  CAS PubMed Web of Science® Google Scholar
• 458Bryon, L., et al. (2018) Org. Process. Res. Dev. 22, 1289.
  10.1021/acs.oprd.8b00210

  Web of Science® Google Scholar
• 459Duan, S., et al. (2017) Org. Process. Res. Dev. 21, 1340.
  10.1021/acs.oprd.7b00187

  CAS Web of Science® Google Scholar
• 460Pfizer, (2014) US 8 680 111, USA-prior. 2012.
  Google Scholar
• 461Array Biopharma, (2007) US 7 235 537, USA-prior. 2012.
  Google Scholar
• 462Array Biopharma, (2011) US 8 039 637, USA-prior. 2005.
  Google Scholar
• 463Novartis/Array Biopharma, (2017) US 9 238 627, USA-prior. 2012.
  Google Scholar
• 464Array Biopharma, (2008) US 7 425 637, USA-prior. 2003.
  Google Scholar
• 465Array Biopharma, (2015) US 9 156 795, USA-prior. 2005.
  Google Scholar
• 466Array Biopharma/AstraZeneca, (2017) US 9 562 017, USA-prior. 2005.
  Google Scholar
• 467Novartis/Astex, (2014) US 8 685 980, USA-prior. 2009.
  Google Scholar
• 468Novartis/Astec, (2015) US 9 193 732, USA-prior. 2010.
  Google Scholar
• 469Frederick, M.O., et al. (2015) Tetrahedron Lett. 56, 949.
  10.1016/j.tetlet.2014.12.082

  CAS Web of Science® Google Scholar
• 470Frederick, M.O., et al. (2017) Org. Process. Res. Dev. 21, 1447.
  10.1021/acs.oprd.7b00234

  CAS Web of Science® Google Scholar
• 471Eli Lilly, (2010) US 7 855 211, EP-prior. 2008.
  Google Scholar
• 472Tsou, H.-R., et al. (2005) J. Med. Chem. 48, 1107.
  10.1021/jm040159c

  CAS PubMed Web of Science® Google Scholar
• 473Wyeth, (2008) US 7 399 865, USA-prior. 2003.
  Google Scholar
• 474Yin, L., et al. (2019) Synthesis 51, 2660.
  10.1055/s-0037-1610706

  CAS Web of Science® Google Scholar
• 475Array Biopharma, (2014) US 8 648 087, USA-prior. 2005.
  Google Scholar
• 476TargeGen, (2009) US 7 528 143, USA-prior. 2005.
  Google Scholar
• 477Impact Biomedicines, (2019) US 10 391 094, USA-prior. 2010.
  Google Scholar
• 478Davis, R.R., et al. (2021) Structural Insights into JAK-2 Inhibition by Ruxolitinib, Fedratinib and Derivatives, J. Med. Chem. 64, 2228.
  10.1021/acs.jmedchem.0c01952

  CAS PubMed Web of Science® Google Scholar
• 479Kirin Beer, (2004) US 6 821 987, JP-prior. 2001.
  Google Scholar
• 480Kirin Beer, (2007) US 7 211 587, JP-prior. 2001.
  Google Scholar
• 481MSD, (2016) US 9 290 504, USA-prior. 2011.
  Google Scholar
• 482Acerta, (2017) US 9 796 721, USA-prior. 2015.
  Google Scholar
• 483Acerta, (2019) US 10 272 083, USA-prior. 2014.
  Google Scholar
• 484Guo, Y., et al. (2019) J. Med. Chem. 62, 7923.
  10.1021/acs.jmedchem.9b00687

  CAS PubMed Web of Science® Google Scholar
• 485BeiGene, (2016) US 9 447 106, USA-prior. 2013.
  Google Scholar
• 486Celgene, (2012) US 8 158 653, USA-prior. 1999.
  Google Scholar
• 487Celgene, (2012) US 8 198 262, USA-prior. 2002.
  Google Scholar
• 488Celgene, (2012) US 8 204 763, USA-prior. 1998.
  Google Scholar
• 489Scott, W.J., et al. (2016) ChemMedChem 11, 1517.
  10.1002/cmdc.201600148

  CAS PubMed Web of Science® Google Scholar
• 490Bayer, (2009), US 7 511 041, EP-prior. 2002.
  Google Scholar
• 491Bayer, (2013), US 8 466 283, USA-prior. 2006.
  Google Scholar
• 492Bayer, (2017), US 9 636 344, EP-prior. 2011.
  Google Scholar
• 493Furet, P., et al. (2013) Bioorg. Med. Chem. Lett. 23, 3741.
  10.1016/j.bmcl.2013.05.007

  CAS PubMed Web of Science® Google Scholar
• 494Novartis, (2012) US 8 227 462, EP-prior. 2008.
  Google Scholar
• 495Novartis, (2014) US 8 710 085, USA-prior. 2008.
  Google Scholar
• 496Winkler, D.G., et al. (2013) Chem. Biol. 20, 1364.
  10.1016/j.chembiol.2013.09.017

  CAS PubMed Web of Science® Google Scholar
• 497Intellikine, (2012) US 8 193 182, USA-prior. 2008.
  Google Scholar
• 498Infinity, (2014) US 8 809 349, USA-prior. 2011.
  Google Scholar
• 499Intellikine, (2015) US 9 216 982, USA-prior. 2008.
  Google Scholar
• 500Infinity, (2017) US 9 840 505, USA-prior. 2011.
  Google Scholar
• 501Novartis, (2011) US 7 973 031, USA-prior.2001.
  Google Scholar
• 502Novartis, (2012) US 8 222 244, USA-prior.2001.
  Google Scholar
• 503Novartis, (2007) US 8 575 146, USA-prior.2003.
  Google Scholar
• 504Chao, Q., et al. (2009) J. Med. Chem. 52, 7808.
  10.1021/jm9007533

  CAS PubMed Web of Science® Google Scholar
• 505Ambit Bioscience, (21.10.2014) US 8 865 710, USA-prior. 2009.
  Google Scholar
• 506Ambit Bioscience, (31.01.2017) US 9 555 040, USA-prior. 2009.
  Google Scholar
• 507Array, (2013) US 8 513 263, USA-prior. 2008.
  Google Scholar
• 508Array, (2015) US 9 127 013, USA-prior. 2008.
  Google Scholar
• 509Array, (2019) US 10 172 861, USA-prior. 2014.
  Google Scholar
• 510Astellas, (2015) US 8 969 336, JP-prior. 2009.
  Google Scholar
• 511Astellas, (2016) US 9 487 491, JP-prior. 2009.
  Google Scholar
• 512Astellas, (2020) US 10 786 500, JP-prior. 2015.
  Google Scholar
• 513Menichincheri, M., et al. (2016) J. Med. Chem. 59, 3392.
  10.1021/acs.jmedchem.6b00064

  CAS PubMed Web of Science® Google Scholar
• 514 Nerviano, (2012) US 8 299 057, EP-prior. 2007.
  Google Scholar
• 515 Nerviano, (2015) US 9 085 565, EP-prior. 2012.
  Google Scholar
• 516Lamb, Y.N. (2019) Drugs 79, 1805.
  10.1007/s40265-019-01210-0

  CAS PubMed Web of Science® Google Scholar
• 517Chen, D., et al. (2019) Synthesis 51, 2564.
  10.1055/s-0037-1612421

  CAS Web of Science® Google Scholar
• 518Plexxikon, (2011) US 7 893 075, USA-prior. 2006.
  Google Scholar
• 519Plexxikon, (2017) US 9 802 932, USA-prior. 2015.
  Google Scholar
• 520Astex Therap., (2014) US 8 895 601, USA-prior. 2010.
  Google Scholar
• 521Astex Therap., (2016) US 9 464 071, USA-prior. 2010.
  Google Scholar
• 522Astex Therap., (2021) US 10 898 482, EP-prior. 2015.
  Google Scholar
• 523Incyte, (2010) US 7 767 675, USA-prior. 2006.
  Google Scholar
• 524Incyte, (2013) US 8 420 645, USA-prior. 2008.
  Google Scholar
• 525Incyte, (2013) US 8 461 330, USA-prior. 2006.
  Google Scholar
• 526Incyte, (2014) US 8 901 123, USA-prior. 2008.
  Google Scholar
• 527Novartis, (2020) US 10 596 178, USA-prior. 2014.
  Google Scholar
• 528Blueprint Medicines, (2015) US 9 200 002, USA-prior. 2013.
  Google Scholar
• 529Blueprint Medicines, (2018) US 9 944 651, USA-prior. 2013.
  Google Scholar
• 530Blueprint Medicines, (2018) US 9 994 575, USA-prior. 2013.
  Google Scholar
• 531Deciphera, (2012), US 8 188 113, USA-prior. 2006.
  Google Scholar
• 532Deciphera, (2013) US 8 461 179, USA-prior. 2012.
  Google Scholar
• 533Deciphera, (2015) US 8 940 756, USA-prior. 2012.
  Google Scholar
• 534Incyte, (2017) US 9 611 267, USA-prior. 2012.
  Google Scholar
• 535Weiner, L.M., et al. (2010) Monoclonal Antibodies: Versatile Platforms for Cancer Immunotherapy, Nat. Rev. Immunol. 10, 317–327.
  10.1038/nri2744

  CAS PubMed Web of Science® Google Scholar
• 536Rajewsky, K. (2019) The Advent and Rise of Monoclonal Antibodies, Nature 575, 47–49.
  10.1038/d41586-019-02840-w

  CAS PubMed Web of Science® Google Scholar
• 537Evans, J.B. and Syed, B.A. (2014) Next-generation Antibodies, Nat. Rev. Drug Discov. 13, 413–414.
  10.1038/nrd4255

  CAS PubMed Web of Science® Google Scholar
• 538Germinario, C., et al. (2018) Patentability of Antibodies for Therapeutic Use in Europe, Nat. Biotechnol. 36, 402–405.
  10.1038/nbt.4134

  CAS PubMed Web of Science® Google Scholar
• 539Chari, R.J.V., et al. (2014) Antibody-Drug Conjugate: An Emerging Concept in Cancer, Angew. Chem. Int. Ed. 53, 3796–3827.
  10.1002/anie.201307628

  CAS PubMed Web of Science® Google Scholar
• 540Lambert, J.M. and Chari, R.J.V. (2014) Ado-Trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer, J. Med. Chem. 57, 3796–3827.
  10.1021/jm500766w

  Web of Science® Google Scholar
• 541Immunogen, (2013) US 8 563 509, USA-prior. 2007.
  Google Scholar
• 542Munchhof, M.J., et al. (2012) ACS Med, Chem. Lett. 3, 106–111.
  CAS Google Scholar
• 543Peng, Z., et al. (2014) Org. Lett. 16, 860–863.
  10.1021/ol403630g

  CAS PubMed Web of Science® Google Scholar
• 544Pfizer, (2012) US 8 148 401, USA-prior. 2007.
  Google Scholar
• 545Jones, P., et al. (2015) J. Med. Chem. 58, 3302–3314.
  10.1021/jm5018237

  CAS PubMed Web of Science® Google Scholar
• 546Wallace, D.J., et al. (2011) Org. Process. Res. Dev. 15, 831–840.
  10.1021/op2000783

  CAS Web of Science® Google Scholar
• 547Chung, C.K., et al. (2014) Org. Process. Res. Dev. 18, 215–227.
  10.1021/op400233z

  CAS Web of Science® Google Scholar
• 548Ist. Di Ricerche P. Angeletti, (2011) US 8 071 623, GB-prior. 2007.
  Google Scholar
• 549Agouron, (2002) US 6 495 541, USA-prior. 1999.
  Google Scholar
• 550Pfizer, (2015) US 9 045 487, USA-prior. 2010.
  Google Scholar
• 551Clovis Oncology, (2018) US 10 130 636, USA-prior. 2014.
  Google Scholar
• 552Gilmore, A.T., et al. (2012) Org. Process. Res. Dev. 16, 1897–1904.
  10.1021/op200238p

  Web of Science® Google Scholar
• 553Wang, B., et al. (2016) J. Med. Chem. 59, 335–357.
  10.1021/acs.jmedchem.5b01498

  CAS PubMed Web of Science® Google Scholar
• 554BioMarin, (2011) US 8 012 976, USA-prior. 2008.
  Google Scholar
• 555Medivation, (2019) US 10 189 837, USA-prior. 2010.
  Google Scholar
• 556Ku, Y.-Y., et al. (2019) Large-Scale Synthesis, J. Org. Chem. 84, 4814–4829.
  10.1021/acs.joc.8b02750

  CAS PubMed Web of Science® Google Scholar
• 557Agios, (2016) US 9 512 107, USA-prior. 2012.
  Google Scholar
• 558Agios, (2018) US 10 093 654, USA-prior. 2013.
  Google Scholar
• 559Popovici-Muller, J., et al. (2018) ACS Med. Chem. Lett. 9, 300–305.
  10.1021/acsmedchemlett.7b00421

  CAS PubMed Web of Science® Google Scholar
• 560Agios, (2016) US 9 474 779, CN-prior. 2012.
  Google Scholar
• 561Agios, (2017) US 9 850 277, CN-prior. 2012.
  Google Scholar
• 562Karyopharm, (2015) US 8 999 996, USA-prior. 2011.
  Google Scholar
• 563Karyopharm, (2015) US 9 079 865, USA-prior. 2011.
  Google Scholar
• 564Karyopharm, (2017) US 9 714 226, USA-prior. 2012,
  Google Scholar
• 565 Schering AG, (1960) DE 1 074 582, DE-prior. 1958.
  Google Scholar
• 566Hughes, D.L. (2020) Org. Process. Res. Dev. 24, 347–362.
  10.1021/acs.oprd.0c00005

  CAS Web of Science® Google Scholar
• 567University of California, (2013) US 8 445 507, USA-prior. 2006.
  Google Scholar
• 568University of California, (2014) US 8 802 689, USA-prior. 2006.
  Google Scholar
• 569University of California, (2016) US 9 388 159, USA-prior. 2006.
  Google Scholar
• 570Orion, (2015) US 8 975 254, USA-prior. 2009.
  Google Scholar
• 571Orion, (2018) US 10 010 530, FI-prior. 2015.
  Google Scholar
• 572Orion, (2019) US 10 383 853, FI-prior. 2015.
  Google Scholar
• 573Miwa, K., et al. (2011) J. Med. Chem. 54, 4998–5012.
  10.1021/jm200216q

  CAS PubMed Web of Science® Google Scholar
• 574Takeda, (2007) US 7 300 935, JP-prior. 2003.
  Google Scholar
• 575Takeda, (2011) US 8 058 280, JP-prior. 2003.
  Google Scholar
• 576Takeda, (2019) US 10 350 170, JP-prior. 2015.
  Google Scholar
• 577Myovant, (2020) US 10 786 501, USA-prior. 2016.
  Google Scholar
• 578Pommier, Y. (2009) Chem. Rev. 109, 2894–2902.
  10.1021/cr900097c

  CAS PubMed Web of Science® Google Scholar
• 579Scott, J.D. and Williams, R.M. (2002) Chem. Rev. 102, 1669–1730.
  10.1021/cr010212u

  CAS PubMed Web of Science® Google Scholar
• 580Hollstein, U. (1974) Chem. Rev. 74, 625–652.
  10.1021/cr60292a002

  CAS Web of Science® Google Scholar
• 581Rajski, S.R. and Williams, R.M. (1998) Chem. Rev. 98, 2758–2763.
  10.1021/cr9800199

  Web of Science® Google Scholar
• 582Ward, R.A., et al. (2021) Challenges and Opportunities in Cancer Drug Resistance, Chem. Rev. 121, 3297–3351.
  10.1021/acs.chemrev.0c00383

  CAS PubMed Web of Science® Google Scholar
• 583Lightfood, H.L., et al. (2019) Evolution of Small Molecule Kinase Drugs, ACS Med. Chem. Lett. 10, 153–160.
  10.1021/acsmedchemlett.8b00445

  PubMed Web of Science® Google Scholar
• 584Review publication:Agianian, B. and Gavathiotis, E. (2018) Current Insights of BRAF Inhibitors in Cancer, J. Med. Chem. 61, 5775–5793.
  10.1021/acs.jmedchem.7b01306

  CAS PubMed Web of Science® Google Scholar
• 585Xie, Z., et al. (2021) J. Med. Chem. 64, 1283–1345.
  10.1021/acs.jmedchem.0c01511

  CAS PubMed Web of Science® Google Scholar
• 586Alvarez, R., et al. (2014) Functions, Therapeutic Applications, and Synthesis of Retinoids and Carotenoids, Chem. Rev. 114, 1–125.
  10.1021/cr400126u

  CAS PubMed Web of Science® Google Scholar
• 587Song, R., et al. (2021) Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities, J. Med. Chem. 64, 2851–2877.
  10.1021/acs.jmedchem.0c01640

  CAS PubMed Web of Science® Google Scholar
• 588Miller, T.A., et al. (2003) Histone Deacetylase Inhibitors, J. Med. Chem. 46, 5097–5116.
  10.1021/jm0303094

  CAS PubMed Web of Science® Google Scholar
• 589Zhang, X.-H., et al. (2021) A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity, J. Med. Chem. 64, 1362–1391.
  10.1021/acs.jmedchem.0c01782

  CAS PubMed Web of Science® Google Scholar
• 590Galperin, I., et al. (2019) Inhibiting Hedgehog: An Update on Pharmacological Compounds and Targeting Strategies, J. Med. Chem. 62, 8392–8411.
  10.1021/acs.jmedchem.9b00188

  CAS PubMed Web of Science® Google Scholar
• 591Ferraris, D.V. (2010) Evolution of Poly(ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic, J. Med. Chem. 53, 4561–4584.
  10.1021/jm100012m

  CAS PubMed Web of Science® Google Scholar
• 592 Goodman & Gilman's, (2011) Section IV, Chapter 35, Immunosuppressants, Tolerogens, and Immunostimulants, pp. 1005–1029.
  Google Scholar
• 593 Goodman & Gilman's, (2011) Section IV, Chapters 37, Hematopoietic Agents, pp. 1067–1097.
  Google Scholar
• 594Teitelbaum, D., et al. (1971) Eur. J. Immunol. 1, 242.
  10.1002/eji.1830010406

  CAS PubMed Google Scholar
• 595 Yeda Res, (1974) US 3 849 550, IL-prior. 1971.
  Google Scholar
• 596 Yeda Res, (1998) US 5 800 808, USA-prior. 1994.
  Google Scholar
• 597Sandoz, (2013) US 8 536 305, USA-prior. 2004.
  Google Scholar
• 598Brune, M., et al. (2006) Blood 108 (1), 88–96.
  10.1182/blood-2005-10-4073

  CAS PubMed Web of Science® Google Scholar
• 599Romero, A., et al. (2009) Scand. J. Immunol. 70 (3), 194–205.
  10.1111/j.1365-3083.2009.02303.x

  CAS PubMed Web of Science® Google Scholar
• 600 Ciba-Geigy, (1983) US 4 406 890, USA-prior. 1981.
  Google Scholar
• 601Bridger, G.J., et al. (1995) J. Med. Chem. 38, 366–378.
  10.1021/jm00002a019

  CAS PubMed Web of Science® Google Scholar
• 602 Johnson Matthey, (1997) US 5 606 053, USA-prior. 1995.
  Google Scholar
• 603Achmatowicz, M. and Hegedus, L.S. (2003) J. Org. Chem. 68, 6435.
  10.1021/jo030146r

  CAS PubMed Web of Science® Google Scholar
• 604De Clercq, E. (2003) Nat. Rev. Drug Discov. 2, 581–587.
  10.1038/nrd1134

  CAS PubMed Web of Science® Google Scholar
• 605 Genzyme, (2011) US 7 897 590, USA-prior.2001.
  Google Scholar
• 606Raeymaekers, A.H.M., et al. (1966) J. Med. Chem. 9, 545.
  10.1021/jm00322a023

  CAS PubMed Web of Science® Google Scholar
• 607Bullock, M.W., et al. (1968) J. Med. Chem. 11, 169.
  10.1021/jm00309a002

  CAS PubMed Web of Science® Google Scholar
• 608Janssen, (1966) US 3 274 209, USA-prior. 1964.
  Google Scholar
• 609Hoechst, (1996) US 5 494 911, DE-prior. 1990.
  Google Scholar
• 610Aventis, (2002) US 6 794 410, USA-prior. 2001.
  Google Scholar
• 611Man, W., et al. (2009) J. Med. Chem. 52, 1522.
  10.1021/jm900210d

  CAS PubMed Web of Science® Google Scholar
• 612Celgene, (2000) US 6 020 358, USA-prior. 1998.
  Google Scholar
• 613Celgene, (2008) US 7 427 638, USA-prior. 2002.
  Google Scholar
• 614Jiaojiao, X., et al. (2016) J. Chem. Res. 40, 205.
  10.3184/174751916X14569294811333

  Google Scholar
• 615Incyte, (2012) US 8 158 616, USA-prior. 2008.
  Google Scholar
• 616Incyte, (2013) US 8 420 629, USA-prior. 2008.
  Google Scholar
• 617Scripps, (2013) US 8 481 573, USA-prior. 2008.
  Google Scholar
• 618EMD, (2010) US 7 713 947, EP-prior. 2004.
  Google Scholar
• 619EMD, (2013) US 8 377 903, EP-prior. 2004.
  Google Scholar
• 620Pan, S., et al. (2013) ACS Med. Chem. Lett. 4, 333.
  10.1021/ml300396r

  CAS PubMed Web of Science® Google Scholar
• 621 Novartis, (2011) US 7 939 519, USA-prior. 2003.
  Google Scholar
• 622 Novartis, (2013) US 8 492 441, USA-prior. 2008.
  Google Scholar
• 623Abbvie, (2015) US 8 962 629, USA-prior. 2008.
  Google Scholar
• 624Abbvie, (2018) US 9 951 080, USA-prior. 2015.
  Google Scholar
• 625Isotechnika, (2008) US 7 332 472, USA-prior. 2001.
  Google Scholar
• 626Aurinia, (2019) US 10 286 036, USA-prior. 2017.
  Google Scholar
• 627 Fumapharm, (2003) US 6 509 376, DE-prior. 1998.
  Google Scholar
• 628 Fumapharm, (2008) US 7 320 999, DE-prior. 1998.
  Google Scholar
• 629 Biogen Idec, (2013) US 8 399 514, USA-prior. 2008.
  Google Scholar

Further Reading

• Adams, J.L., et al. (2015) Big Opportunities for Small Molecules in Immune-Oncology, Nat. Rev. Drug Discov. 14, 603–622.
  10.1038/nrd4596

  CAS PubMed Web of Science® Google Scholar
• Airley, R. (2009) Cancer Chemotherapy, Wiley-Blackwell, Chichester.
  Google Scholar
• Al-Lazikani, B., et al. (2012) Combinatorial Drug Therapy for Cancer in the Post-genomic Era, Nat. Biotechnol. 30, 1–13. (A detailed review).
  10.1038/nbt.2284

  CAS PubMed Web of Science® Google Scholar
• Cragg, G.M., et al. (2009) Impact of Natural Products on Developing New Anti-cancer Agents, Chem. Rev. 109, 3012–3043.
  10.1021/cr900019j

  CAS PubMed Web of Science® Google Scholar
• Dobbelstein, M. and Moll, U. (2014) Targeting Tumour-Supportive Cellular Machineries in Anticancer Drug Development, Nat. Rev. Drug Discov. 13, 179–196. (Review regarding also the history of cancer therapies).
  10.1038/nrd4201

  CAS PubMed Web of Science® Google Scholar
• IMS Institute for Healthcare Informatics: (a) Global Oncology Trend Report, May 2015 (Development in cancer treatments, market dynamics, patient access and value); (b) Global Oncology Trend Report, June 2016 (A review of 2015 and outlook to 2020).
  Google Scholar
• Manley, P.W., et al. (2015) Progress into the era of genomically targeted cancer drugs: 50 years of anticancer medicinal chemistry, in Medicinal Chemistry Reviews, vol. 50, Med. Chem. Division of the ACS; (a) Chapter 8, p. 187–223: Targeting Protein kinases, Lipid kinases, Protein-Protein interactions regulating apoptosis, aberrant DNA methylation, Histones, Hormones and hormone receptors, RAS. (b) Chapter 9, p. 225–237: Targeting the B-cell receptor pathway in hematological malignancies with Btk inhibitors, PI3Kδ inhibitors, Syk inhibitors.
  Google Scholar
• Missailidis, S. (2008) Anticancer Therapeutics, Wiley-Blackwell, Chichester.
  10.1002/9780470697047

  Google Scholar
• National Cancer Institute, (2015) What is Cancer? www.cancer.gov/about-cancer/what-is-cancer (accessed March 2017).
  Google Scholar
• NCA/NIH (Office of Cancer Nanotechnology Research, Center for Strategic Scientific Initiatives) (2015) Cancer Nanotechnology Plan 2015, 257 pages; (describes research results and challenges for the application of Nanotechnology to anticancer drug delivery and diagnostic methods, e.g., Manufacturing Challenges of Nano-Products).
  Google Scholar
• Various Authors (2009) Chem. Rev. 109 (7), 2859–3208; 17 review articles on cancer chemotherapeutics.
  10.1021/cr900208x

  PubMed Web of Science® Google Scholar
• Various Authors (2013) Nature Outlook: Cancer Immunotherapy, Nature 504 (7480), S1–S17.
  10.1038/504S1a

  CAS PubMed Web of Science® Google Scholar
• Ward, R.A., et al. (2021) Challenges and Opportunities in Cancer Drug Resistance, Chem. Rev. 121, 3297–3351.
  10.1021/acs.chemrev.0c00383

  CAS PubMed Web of Science® Google Scholar
• World Health Organisation (2015) 19th WHO Model List of Essential Medicines.
  Google Scholar
• World Health Organisation (2020) C World Cancer Report 2020, International Agency for Research on Cancer (IARC) with Data of the Year 2018, Lyon.
  Google Scholar
• Zur Hausen, H. (2009) The Search for Infectious Causes of Human Cancers: Where and Why (Nobel Lecture), Angew. Chem. Int. Ed. 48, 5798–5808.
  10.1002/anie.200901917

  CAS PubMed Web of Science® Google Scholar
• Zolot, R.S., et al. (2013) Antibody-Drug Conjugates, Nat. Rev. Drug Discov. 12, 259–260.
  10.1038/nrd3980

  CAS PubMed Web of Science® Google Scholar

Ullmann's Encyclopedia of Industrial Chemistry

Browse other articles of this reference work:

• BROWSE BY TOPIC
• BROWSE A-Z

• References

• Related

• Information

Close Figure Viewer

Previous FigureNext Figure

Caption